医学
弥漫性大B细胞淋巴瘤
嵌合抗原受体
重症监护医学
肿瘤科
淋巴瘤
内科学
移植
人口
免疫疗法
癌症
环境卫生
作者
Swetha Kambhampati,Alex F. Herrera,June-Wha Rhee
标识
DOI:10.1016/j.jaccao.2023.05.001
摘要
Anthracycline-containing therapy is the cornerstone of frontline treatment for diffuse large B-cell lymphoma (DLBCL), and autologous stem cell transplantation, and more recently, chimeric antigen receptor T-cell therapy are the primary treatment options for relapsed refractory DLBCL. Given these therapies are all associated with cardiovascular toxicities, patients with underlying cardiac comorbidities are severely limited in treatment options. The focus of this review is to outline the cardiotoxicities associated with these standard treatments, explore strategies developed to mitigate these toxicities, and review novel treatment strategies for patients with underlying cardiovascular comorbidities. DLBCL patients with underlying cardiac complications are a high-risk patient population who require complicated management strategies that utilize a multidisciplinary approach with collaboration between cardiologists and oncologists.
科研通智能强力驱动
Strongly Powered by AbleSci AI